In the context of inflammatory bowel disease (IBD), ASX supplementation has been shown to reduce colonic inflammation by downregulating cytokines such as TNF-α, IL-1β, and IL-6, while enhancing endogenous antioxidant defenses including superoxide dismutase and glutathione peroxidase. This evidence concerns the gene IL1B and inflammatory bowel disease.